Influence of endothelial progenitor cells mobilized by rosuvastatin on ventricular remodeling in patients with myocardial infarction／ / 心血管康复医学杂志

ABSTRACT

To observe influence of endothelial progenitor cells (EPCs) mobilized by rosuvastatin on ven‐tricular remodeling in patients with myocardial infarction (MI).Methods: A total of 128 MI patients received PCI treated in our department from Jan 2017 to Jan 2018 were selected , randomly and equally divided into routine treat‐ment group and rosuvastatin group (received rosuvastatin based on routine treatment group ) , both groups were con‐tinuously treated for 28d .Peripheral blood percentage of EPCs before and 28d after treatment , LVEF , LVESd and LVEDd before and six months after treatment , and incidence rate of adverse reactions were measured and compared between two groups .Results: Compared with before treatment , there was significant rise in peripheral blood per‐centage of EPCs [ (0. 64 ± 0. 15)% vs.(1. 08 ± 0.23)%] in only rosuvastatin group on 28d after treatment , P＝0.001 ;and was significantly higher than that of routine treatment group [(1.08 ± 0.23)% vs.(0.58 ± 0.12)%] , P＝ 0. 001. Compared with before treatment , there was significant rise in LVEF , and significant reductions in LVEDd and LVESd in two groups on six months after treatment , P＝0.001 all ;compared with routine treatment group , there was significant rise in LVEF [ (52.24 ± 7.18)% vs.(58. 36 ± 8.62)%] , and significant reductions in LVESd [ (33.46 ± 5. 04) mm vs.(30. 26 ± 4. 15) mm] and LVEDd [ (56.17 ± 8. 24) mm vs.(51. 38 ± 7.62) mm] in rosuvastatin group , P＝0. 001 all .There was no significant difference in incidence rate of adverse reactions be‐tween two groups , P＝0. 752. Conclusion: Rosuvastatin can mobilize EPCs to inhibit ventricular remodeling , sig‐nificantly improve cardiac function with good safety in patients with myocardial infarction , which is worth exten‐ding .